106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies at GuidelineCentral.com
Copyright © 2022 All rights reserved
ACRJIAN02223a
Disclaimer
is pocket guide attempts to define principles of practice that should produce high-quality patient
care. It is applicable to specialists, primary care, and providers at all levels. is pocket guide should
not be considered exclusive of other methods of care reasonably directed at obtaining the same
results. e ultimate judgment concerning the propriety of any course of conduct must be made by
the clinician aer consideration of each individual patient situation. Neither IGC, the American
College of Rheumatology, nor the authors endorse any product or service associated with the
distributor of this clinical reference tool.
Abbreviations
ALT, alanine transaminase; bDMARD, biologic disease-modifying antirheumatic
drug ; CBC, complete blood count; CDC, Centers for Disease Control and Prevention;
csDMARD, conventional synthetic disease modifying anti-rheumatic drugs; DMARD;
disease-modifying antirheumatic drug ; GC, glucocorticoids; IAGC, intra-articular
glucocorticoid; JAK, Janus kinase; JIA, juvenile idiopathic arthritis; LEF, leflunomide;
NSAID, non-steroidal anti-inflammatory drugs; TB, tuberculosis; TNFi, tumor necrosis
factor inhibitors; tsDMARD, targeted synthetic DMARD; LFT, liver function test;
OBRM, other biologic response modifiers; OT, occupational therapy; PT, physical therapy;
ULN, upper limit of normal
Source
Onel KB, Horton DB, Lovell DJ, et al. 2021 American College of Rheumatolog y Guideline
for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic
erapies, Medication Monitoring, Immunizations, and Imaging, Arthritis & Rheumatolog y,
2022 Mar 2. doi: 10.1002/art.42036. Epub ahead of print.
